Denali Therapeutics Inc. announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which evaluates Denali?s eIF2B agonist DNL343. Regimen G is co-led by Suma Babu, MBBS, MPH, and Sabrina Paganoni, MD, PhD, physician investigators at the Healey & AMG Center for ALS at MGH.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.5 USD | +3.82% | +8.47% | -4.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.47% | 2.82B | |
+7.29% | 111B | |
+11.20% | 106B | |
-12.48% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.56% | 16.81B | |
+37.62% | 12.54B | |
-24.25% | 8.09B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial